Clinical trials: Elderly Lymphoma Patients
Diffuse Large B-Cell Lymphoma
A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
This is a study incorporating brentuximab vedotin and dose attenuated rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) into initial therapy for elderly patients with DLBCL.
- Trial name
- BV mini CHP (NCT02734771)
- Testing
- Brentuximab vedotin, Rituximab, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Patrick Reagan
Non Hodgkin Lymphoma, Follicular Lymphoma
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma
This is a prospective multicenter phase II pilot trial designed with the purpose of dose finding to evaluate the efficacy and safety of treatment with Lenalidomide plus R-CHOP21 (LR-CHOP21) for elderly patients with untreated…
- Trial name
- REAL07 (NCT00907348)
- Testing
- LR-CHOP21
- Where
- 18 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Lymphoma
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
As the most common subtype of lymphoma, diffuse large B-cell lymphoma (DLBCL) is an aggressive but potentially curable malignancy.
- Trial name
- NCT05290090
- Testing
- Rituximab, Lenalidomide, Zanubrutinib and RCHOP
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Zhejiang Cancer Hospital
Diffuse Large B Cell Lymphoma
Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)
This is a prospective, single-center, open-label, single-arm clinical study designed to evaluate the efficacy and safety of the Zanubrutinib, Lenalidomide and Rituximab (ZR2) regimen in elderly treatment-naive patient with…
- Trial name
- NCT04460248
- Testing
- Zanubrutinib, Lenalidomide and Rituximab (ZR2)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Breast Cancer, Colorectal Cancer
Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer
The main objective of study is to describe the priorities of elderly patients (70 years and over) undergoing a first medical treatment for cancer, at initiation of treatment and after 3 months of treatment.
- Conditions
- Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer
- Trial name
- PRIORITY (NCT02821793)
- Testing
- Consultation, evaluation questionnaire, Geriatric consultation, evaluation questionnaire
- Where
- France
- Volunteers
- 346 people
- Sponsor
- Institut Bergonié
Elderly Lymphoma Patients
Evaluation of the Application of PEGylated Recombinant Human Granulocyte Stimulating Factor Injection (PEG-rhG-CSF) in Chemotherapy of Elderly Lymphoma Patients
A multicenter, open, one-arm clinical study evaluated the efficacy and safety of Jinyouli in preventing neutropenia after chemotherapy in elderly lymphoma patients who met the criteria for admission.
- Trial name
- NCT03870412
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 485 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Leukemia
AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia
RATIONALE: AT9283 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/IIa clinical trial is studying the side effects and best dose of AT9283 in treating young…
- Trial name
- NCT01431664
- Testing
- multikinase inhibitor AT9283, laboratory biomarker analysis, pharmacological study
- Where
- 5 sites in United Kingdom
- Volunteers
- 7 people
- Sponsor
- Cancer Research UK
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Digital Patient-Reported Assessment in Older Adults With Acute Leukemia
This pilot study will evaluate the feasibility of implementing a structured digital patient-reported assessment pathway in adults aged 65 years or older with acute leukemia at Hospital Universitario Central de Asturias, Oviedo…
- Trial name
- NCT07597590
- Testing
- Digital Patient-Reported Assessment Pathway
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Fundación para la Investigación Biosanitaria del Principado de Asturias
Diffuse Large Cell Lymphoma
ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma
This study is a multicentric randomized trial evaluating the efficacy of the combination R-ACVBP in patients 18 to 65 years with low risk localized diffuse large B-cell lymphoma.
- Trial name
- NCT00140660
- Testing
- rituximab
- Where
- 11 sites in Belgium, France and 1 more
- Volunteers
- 223 people
- Sponsor
- Lymphoma Study Association
Diffuse Large B-Cell Lymphoma
Mini-CHOP and Rituximab in Patients Aged Over 80 Years
The purpose of the study is to evaluate efficacy and safety of R-miniCHOP for elderly patients with diffuse large B-Cell lymphoma (DLBC) Lymphoma aged over 80 years by measuring the overall survival.
- Trial name
- NCT01087424
- Testing
- R mini CHOP
- Volunteers
- 150 people
- Sponsor
- Lymphoma Study Association
CD20+ Aggressive B-Cell Lymphoma
OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine
The purpose of this study is to improve the outcome of elderly patients with CD20-Aggressive B-Cell Lymphoma and to reduce the toxicity of standard used Immuno-Chemotherapy by using an optimised schedule of the monoclonal…
- Trial name
- OPTIMAL>60 (NCT01478542)
- Testing
- Conventional Vincristine, Liposomal Vincristine, Ricover-scheme rituximab
- Where
- 127 sites in Germany
- Volunteers
- 1,152 people
- Sponsor
- Universität des Saarlandes
Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia
A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia
The primary objective of the study is to demonstrate non-inferiority of lipegfilgrastim to pegfilgrastim for the duration of severe neutropenia in the first cycle of chemotherapy.
- Trial name
- AVOID (NCT02044276)
- Testing
- lipegfilgrastim, pegfilgrastim
- Where
- 60 sites in Germany, Italy and 1 more
- Volunteers
- 101 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Diffuse Large Cell Lymphoma
ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma
This study is a multicentric trial evaluating the efficacy of R-ACVBP in patients aged 18 to 59 years with high risk diffuse large B-cell lymphoma
- Trial name
- NCT00144807
- Testing
- rituximab, doxorubicin, cyclophosphamide
- Where
- 13 sites in Belgium, France and 1 more
- Volunteers
- 128 people
- Sponsor
- Lymphoma Study Association
Diffuse Large B Cell Lymphoma
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
The proposed study is a prospective, single-center and open-ended study in patients over the age of 70 with treatment-naive diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT05809180
- Testing
- Rituximab, Orelabrutinib, Pomalidomide
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Elderly Patients (>65 Years), Diffuse Large B Cell Lymphoma (DLBCL)
R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL
The study has the purpose to compare R-CHOP versus R-mini-CEOP in elderly patients (>65 years) with Diffuse Large B Cell Lymphoma (DLBCL).
- Trial name
- ANZINTER3 (NCT01148446)
- Testing
- Cyclophosphamide, Doxorubicin, Vincristine
- Where
- 11 sites in Italy
- Volunteers
- 226 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescents with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has come back after treatment…
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric Cancer
- Trial name
- NCT07770698
- Testing
- sonrotoclax, Azacitidine, Inotuzumab ozogamicin
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
Diffuse Large B Cell Lymphoma
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
This prospective, single-arm, multicenter clinical study aims to enroll 30 frail elderly patients with Non-GCB DLBCL. This study is to evaluate the preliminary efficacy and safety of the combination of Polatuzumab, Rituximab, and…
- Trial name
- NCT06530511
- Testing
- Polatuzumab vedotin, Rituximab, Orelabrutinib
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Nantong University
Primary Central Nervous System Lymphoma
Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in elderly patients with primary central nervous system lymphoma (PCNSL).
- Trial name
- NCT02836158
- Testing
- R-IDARAM plus intrathecal chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Navy General Hospital, Beijing
Lymphoma
A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years
RATIONALE: Drugs used in chemotherapy, such as vinblastine, cyclophosphamide, procarbazine, prednisolone, etoposide, mitoxantrone, and bleomycin, work in different ways to stop cancer cells from dividing so they stop growing or…
- Trial name
- NCT00079105
- Testing
- bleomycin sulfate, cyclophosphamide, etoposide
- Where
- 54 sites in Germany, United Kingdom
- Volunteers
- 175 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Newly Diagnosed MYC/BCL2 Double-expressor DLBCL
Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL
This study is a phase II clinical trial and is divided into three stages. Stage 1: Chemotherapy-free phase. All subjects will receive "Serplulimab, Chidamide, and Rituximab (SCR) therapy".
- Trial name
- SCREEN (NCT07538180)
- Testing
- SCR Regimen Sequential with R-CHOP and Maintenance Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University